1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Noonan Syndrome 6: new trials by email Literature Review of Noonan Syndrome 6 trials Research Report on Noonan Syndrome 6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Capmatinib, Ceritinib, Entrectinib - ALK Fusion Protein Expression, BRAF wt Allele | Phase 2 | Terminated | University of California, San Francisco | 1 | 2015-03-26 | 2020-01-27 |
Melanoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
capmatinib (1) · ceritinib (1) · entrectinib (1) · regorafenib (1)
University of California, San Francisco (1)
United States (1)
Adil Daud (1)